- Home
- GBCI vs GRFS Comparison
GBCI vs GRFS Comparison
Compare GBCI & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBCI | GRFS |
|---|---|---|
| Founded | 1955 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.2B |
| IPO Year | 1996 | 2008 |
Fundamental Metrics
Financial Performance| Metric | GBCI | GRFS |
|---|---|---|
| Price | $47.95 | $8.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $56.17 | $10.37 |
| AVG Volume (30 Days) | ★ 1.2M | 756.4K |
| Earning Date | 10-22-2026 | 07-28-2022 |
| Dividend Yield | 2.91% | ★ 3.12% |
| EPS Growth | ★ 18.45 | N/A |
| EPS | ★ 2.18 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.14 | $1.89 |
| Revenue Next Year | $9.24 | $6.20 |
| P/E Ratio | $22.02 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.90 | $6.96 |
| 52 Week High | $54.58 | $9.77 |
Technical Indicators
Market Signals| Indicator | GBCI | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 68.98 |
| Support Level | $47.88 | $7.18 |
| Resistance Level | $50.39 | $8.83 |
| Average True Range (ATR) | 1.20 | 0.26 |
| MACD | -0.13 | 0.04 |
| Stochastic Oscillator | 11.44 | 81.68 |
Price Performance
Historical ComparisonAbout GBCI Glacier Bancorp Inc.
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services through its wholly owned bank subsidiary, Glacier Bank. The group provides a full range of banking services to individuals, small to medium-sized businesses, community organizations, and public entities from several locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, Nevada, and Texas. It offers various banking products and services, including: retail banking, business banking, real estate, commercial, agriculture, and consumer loans; and mortgage origination and loan servicing services, among others.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.